Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

Recruiting now · Not applicable

Conditions studied: Hepatitis B, Acute-On-Chronic Liver Failure

In brief

This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.

Key facts

Study ID

NCT03920618

Run by

Third Affiliated Hospital, Sun Yat-Sen University

People needed

150

Starts

2019-02-21

Expected to finish

2024-12-31

Last updated by the study team

2024-11-29

Who can join

Age: 12 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Positive hepatitis b surface antigen or hepatitis b virus DNA > 0.5 year;
• Age from 12 to 65 years old;
• Serum total bilirubin level > 10 times upper limit of normal;
• Prothrombin time activity < 40% or prothrombin time international ratio > 1.5；
• Do not receive nucleotide/nucleoside analogues treatment in the past half year.

You may not qualify if…

• Other active liver diseases;
• Hepatocellular carcinoma or other malignancy;
• Pregnancy or lactation;
• Human immunodeficiency virus infection or congenital immune deficiency diseases;
• Severe diabetes, autoimmune diseases;
• Other important organ dysfunctions;
• Using glucocorticoid;
• Patients can not follow-up;
• Investigator considering inappropriate.

Where it is running

• Third Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.